A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc., representing investors who purchased or acquired the company’s common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx and certain executives violated the Securities Exchange Act of 1934 by making false or misleading statements regarding the effects of setrusumab on patients with various types of Osteogenesis Imperfecta during its Phase III Orbit study. Specifically, the complaint claims the company created a misleading impression of the reliability of its data and downplayed risks related to the study’s design, particularly the lack of a placebo control group in earlier trials. Investors who suffered substantial losses during the stated period may seek appointment as lead plaintiff in the case.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9649311) on February 05, 2026, and is solely responsible for the information contained therein.